Current prognostic indicators for glioma, including clinical and pathological features, such as Ki67, isocitrate dehydrogenase (IDH), as well as imaging findings from computed tomography (CT) and magnetic resonance imaging (MRI) [9], insufficiently meet precision medicine needs. The gene discussed is IDH1; the disease is central nervous system cancer.